Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IFN-2b in Stage II/III Melanoma
NCT00447356Phase 3Withdrawn
- Sponsor
- Hackensack Meridian Health
- Start
- Jan 2000
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of interferon alfa-2b in melanoma, sponsored by Hackensack Meridian Health. Planned start Jan 2000; status: withdrawn.
02
Drugs
interferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00447356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447356.